Trading Report: Today: Research Analysts Issue Forecasts for Juno Therapeutics Inc’s FY2018 Earnings (JUNO)

Today: Research Analysts Issue Forecasts for Juno Therapeutics Inc’s FY2018 Earnings (JUNO)

Juno Therapeutics Inc (NASDAQ:JUNO) – Equities researchers at FBR & Co reduced their FY2018 earnings estimates for Juno Therapeutics in a research report issued on Wednesday. FBR & Co analyst E. White now expects that the brokerage will post earnings of ($3.48) per share for the year, down from their prior estimate of ($3.28). FBR & Co has a “Market Perform” rating and a $30.00 price objective on the stock.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.05. The business earned $20.80 million during the quarter, compared to analysts’ expectations of $10.98 million. The firm’s revenue for the quarter was up 1200.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.26) earnings per share.

A number of other equities analysts have also recently issued reports on JUNO. Maxim Group reduced their target price on Juno Therapeutics from $80.00 to $50.00 and set a “buy” rating on the stock in a report on Friday, August 5th. Vetr cut Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 target price on the stock. in a report on Tuesday, August 16th. Standpoint Research assumed coverage on Juno Therapeutics in a report on Thursday, August 25th. They set a “buy” rating and a $47.00 target price on the stock. BTIG Research assumed coverage on Juno Therapeutics in a report on Tuesday, August 30th. They set a “sell” rating and a $23.00 price objective on the stock. Finally, Zacks Investment Research upgraded Juno Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $40.40.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down 1.43% during midday trading on Monday, reaching $22.68. The company’s stock had a trading volume of 540,196 shares. The firm’s market cap is $2.33 billion. Juno Therapeutics has a 12 month low of $19.41 and a 12 month high of $57.82. The company has a 50-day moving average price of $27.52 and a 200-day moving average price of $32.91.

Hedge funds and other institutional investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale raised its position in Juno Therapeutics by 27.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the biopharmaceutical company’s stock worth $2,374,000 after buying an additional 12,800 shares during the last quarter. Geode Capital Management LLC raised its position in Juno Therapeutics by 4.2% in the first quarter. Geode Capital Management LLC now owns 423,661 shares of the biopharmaceutical company’s stock worth $16,137,000 after buying an additional 17,205 shares during the last quarter. Alps Advisors Inc. acquired a new position in Juno Therapeutics during the second quarter worth $5,603,000. Bank of New York Mellon Corp raised its position in Juno Therapeutics by 54.7% in the second quarter. Bank of New York Mellon Corp now owns 259,047 shares of the biopharmaceutical company’s stock worth $9,959,000 after buying an additional 91,608 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Juno Therapeutics during the second quarter worth $153,000.

In related news, EVP Robert Azelby sold 12,921 shares of the business’s stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $24.14, for a total transaction of $311,912.94. Following the transaction, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at approximately $1,174,169.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Hans Edgar Bishop sold 23,042 shares of the business’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $30.06, for a total value of $692,642.52. Following the transaction, the chief executive officer now directly owns 2,541,151 shares in the company, valued at $76,386,999.06. The disclosure for this sale can be found here.

About Juno Therapeutics

Related posts

Leave a Comment